Cefdinir
|
Systematic (IUPAC) name |
8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-
ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-
azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid |
Clinical data |
Trade names |
Cefzon |
AHFS/Drugs.com |
monograph |
MedlinePlus |
a698001 |
Pregnancy cat. |
B (US) |
Legal status |
Rx only (US) |
Routes |
Oral |
Pharmacokinetic data |
Bioavailability |
16% to 21% (dose-dependent) |
Protein binding |
60% to 70% |
Metabolism |
Negligible |
Half-life |
1.7 ± 0.6 hours |
Excretion |
Renal |
Identifiers |
CAS number |
91832-40-5 |
ATC code |
J01DD15 |
PubChem |
CID 6915944 |
DrugBank |
DB00535 |
ChemSpider |
5291705 Y |
UNII |
CI0FAO63WC Y |
KEGG |
D00917 Y |
ChEBI |
CHEBI:3485 Y |
ChEMBL |
CHEMBL927 Y |
Chemical data |
Formula |
C14H13N5O5S2 |
Mol. mass |
395.416 g/mol |
SMILES
- O=C2N1/C(=C(/C=C)CS[C@@H]1[C@@H]2NC(=O)C(=N\O)/c3nc(sc3)N)C(=O)O
|
InChI
-
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1 Y
Key:RTXOFQZKPXMALH-GHXIOONMSA-N Y
|
Y (what is this?) (verify)
|
Cefdinir is a third generation oral cephalosporin antibiotic. It was discovered by Fujisawa Pharmaceutical Co., Ltd. "Fujisawa" (now Astellas) and introduced in 1991 under the brand name Cefzon.[1][2] Warner-Lambert licensed this cephalosporin, cefdinir, for marketing in US from Fujisawa, Japan.[3] Abbott obtained U.S. marketing rights to Omnicef (Cefdinir) in December 1998 through an agreement with Warner-Lambert Company.[4] It was approved by FDA on Dec 4, 1997.[5] It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott and Cefdiel by Ranbaxy.
As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.[6]
Contents
- 1 Mechanism of action
- 2 Indications
- 3 Susceptible organisms
- 4 Side effects
- 5 Available forms
- 6 "Blood" in the stool
- 7 References
- 8 External links
|
Mechanism of action
Main article: Cephalosporin
Indications
Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.
Susceptible organisms
Cefdinir is a bacteriocidal antibiotic. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria.
Side effects
Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."[7]
Available forms
Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.
"Blood" in the stool
The pediatric version of cefdinir can bind to iron in the digestive tract; in rare cases, this causes a rust or red discoloration of the stool. Blood typically appears dark brown or black in stool, and testing may confirm which is present.
If the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., a Clostridium difficile infection caused by the antibiotic could be signified.
References
- ^ http://www.astellas.com/en/corporate/news/detail/astellas-filed-lawsuit-against.html
- ^ http://wenku.baidu.com/view/a2ef6330b90d6c85ec3ac6fa.html
- ^ http://www.elsevierbi.com/publications/the-pink-sheet/52/005/comprecin-has-excellent-chance-to-reach-us-market-this-year-dupont-prophenytoin-crosslicense-deal?p=1
- ^ http://www.globenewswire.com/newsarchive/mrx/pages/news_releases.html?d=94045
- ^ http://www.drugs.com/mtm/cefdinir.html
- ^ "2008 Top 200 generic drugs by retail dollars" PDF (399.4 KB). Drug Topics (May 26, 2009). Retrieved on July 24, 2009.
- ^ "Omnicef capsules Patient Information". Abbott Laboratories. February 2004. Archived from the original on 2006-11-18. http://web.archive.org/web/20061118132152/http://www.rxabbott.com/pdf/omnicef_capsules_patient_friendly.pdf. Retrieved 2006-11-24.
External links
Antibacterials: cell envelope antibiotics (J01C-J01D)
|
|
Intracellular |
- inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
|
|
Glycopeptide |
- inhibit PG chain elongation: Vancomycin# (Oritavancin
- Telavancin)
- Teicoplanin (Dalbavancin)
- Ramoplanin
|
|
β-lactams/
(inhibit PBP
cross-links) |
Penicillins
(penams)
|
Extended sp.
|
- aminopenicillins: Amoxicillin#
- Ampicillin# (Pivampicillin
- Hetacillin
- Bacampicillin
- Metampicillin
- Talampicillin)
- Epicillin
- carboxypenicillins: Carbenicillin (Carindacillin)
- Ticarcillin
- Temocillin
- ureidopenicillins: Azlocillin
- Piperacillin
- Mezlocillin
- other: Mecillinam (Pivmecillinam)
- Sulbenicillin
|
|
Narrow sp.
|
β-lactamase sensitive
|
- Benzylpenicillin (G)#: Clometocillin
- Benzathine benzylpenicillin#
- Procaine benzylpenicillin#
- Azidocillin
- Penamecillin
- Phenoxymethylpenicillin (V)#: Propicillin
- Benzathine phenoxymethylpenicillin
- Pheneticillin
|
|
β-lactamase resistant
|
- Cloxacillin# (Dicloxacillin
- Flucloxacillin)
- Oxacillin
- Meticillin
- Nafcillin
|
|
|
|
Penems
|
|
|
Carbapenems
|
- Biapenem
- Ertapenem
- antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Panipenem
|
|
Cephalosporins/Cephamycins
(cephems)
|
1st (PEcK)
|
- Cefazolin#
- Cefacetrile
- Cefadroxil
- Cefalexin
- Cefaloglycin
- Cefalonium
- Cefaloridine
- Cefalotin
- Cefapirin
- Cefatrizine
- Cefazedone
- Cefazaflur
- Cefradine
- Cefroxadine
- Ceftezole
|
|
2nd (HEN)
|
- Cefaclor
- Cefamandole
- Cefminox
- Cefonicid
- Ceforanide
- Cefotiam
- Cefprozil
- Cefbuperazone
- Cefuroxime
- Cefuzonam
- cephamycin (Cefoxitin
- Cefotetan
- Cefmetazole)
- carbacephem (Loracarbef)
|
|
3rd
|
- Cefixime#
- Ceftriaxone#
- antipseudomonal (Ceftazidime#
- Cefoperazone)
- Cefcapene
- Cefdaloxime
- Cefdinir
- Cefditoren
- Cefetamet
- Cefmenoxime
- Cefodizime
- Cefotaxime
- Cefpimizole
- Cefpiramide
- Cefpodoxime
- Cefsulodin
- Cefteram
- Ceftibuten
- Ceftiolene
- Ceftizoxime
- oxacephem (Flomoxef
- Latamoxef ‡)
|
|
4th (antips-)
|
- Cefepime
- Cefozopran
- Cefpirome
- Cefquinome
|
|
5th
|
- Ceftobiprole
- Ceftaroline fosamil
|
|
Veterinary
|
- Ceftiofur
- Cefquinome
- Cefovecin
|
|
|
Monobactams
|
- Aztreonam
- Tigemonam
- Carumonam
- Nocardicin A
|
|
β-lactamase inh.
|
- penam (Sulbactam
- Tazobactam)
- clavam (Clavulanic acid)
|
|
Combinations
|
- Amoxicillin/clavulanic acid#
- Imipenem/cilastatin#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Piperacillin/tazobactam
|
|
|
Other |
- polymyxins/detergent (Colistin
- Polymyxin B)
- depolarizing (Daptomycin)
- hydrolyze NAM-NAG (Lysozyme)
- Gramicidin
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
gr+f/gr+a (t)/gr-p (c)/gr-o
|
drug (J1p, w, n, m, vacc)
|
|
|
|
English, Chinese目的:研究头孢地尼(cefdinir,CE)与牛血清白蛋白(bovine serum albumin,BSA)之间的相互作用。方法:在优化的实验条件下,运用荧光光谱和紫外-可见光谱法研究CE与BSA之间的相互作用。结果:CE可与BSA形成基态复合物�